Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON
奥希替尼联合萨沃替尼克服表皮生长因子受体突变、MET扩增的非小细胞肺癌中获得的MET介导耐药:TATTON
期刊:Cancer Discovery
影响因子:33.3
doi:10.1158/2159-8290.CD-22-0586
Hartmaier, Ryan J; Markovets, Aleksandra A; Ahn, Myung Ju; Sequist, Lecia V; Han, Ji-Youn; Cho, Byoung Chul; Yu, Helena A; Kim, Sang-We; Yang, James Chih-Hsin; Lee, Jong-Seok; Su, Wu-Chou; Kowalski, Dariusz M; Orlov, Sergey; Ren, Song; Frewer, Paul; Ou, Xiaoling; Cross, Darren A E; Kurian, Nisha; Cantarini, Mireille; Jänne, Pasi A